Propanc Biopharma Advances PRP as a Novel Approach for RAS-Driven Cancers
MELBOURNE, Australia, August 12, 2026 Propanc Biopharma, Inc. highlighted the potential of its investigational proenzyme therapy PRP as a...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
MELBOURNE, Australia, August 12, 2026 Propanc Biopharma, Inc. highlighted the potential of its investigational proenzyme therapy PRP as a...
MELBOURNE, Australia, August 6, 2026 Propanc Biopharma announced compelling preclinical and early translational findings for its lead investigational therapy...
ROCKVILLE, Md., August 6, 2026 Theriva Biologics announced that the first patient has been dosed in the VIRAGE2 Phase...
SOUTH SAN FRANCISCO, Calif., July 27, 2026 IDEAYA Biosciences announced the initiation of Part 2 monotherapy expansion in its...
Revolution Medicines, Redwood City, Calif., July 22, 2026 Revolution Medicines announced that the U.S. Food and Drug Administration (FDA)...
RAMAT GAN, Israel, July 20, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) announced that positive Phase 2a clinical trial...
REDWOOD CITY, Calif., July 7, 2026 Revolution Medicines has announced a major regulatory milestone as the European Medicines Agency...
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
REDWOOD CITY, Calif., July 2, 2026 Revolution Medicines announced encouraging Phase 1/2 clinical results for its investigational RAS(ON) G12D-selective...
LUND, Sweden, June 27, 2026 Cantargia AB announced the publication of new preclinical and clinical findings in JCI Insight,...
